FDA.reportPublic FDA data

Kanjinti 21 MG/ML Injectable Solution

RxCUI
2174809
RxNorm name
Kanjinti 21 MG/ML Injectable Solution
Display name
Kanjinti 21 MG/ML Injectable Solution
Full name
Kanjinti 21 MG/ML Injectable Solution
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:10

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761073Kanjintitrastuzumab-anns351(k) BiosimilarRx2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
KanjintiTRASTUZUMAB-ANNSAmgen, Inc9a94f5b2-b84e-4987-8ea1-c4346db5a5fa2026-06-23Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2174809

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
9a94f5b2-b84e-4987-8ea1-c4346db5a5faKANJINTI 420 MG in 20 mL Injectable Solution [PSN] · trastuzumab-anns 21 MG/ML Injectable Solution [Kanjinti] [SBD] · Kanjinti 21 MG/ML Injectable Solution [SY] · Kanjinti 420 MG per 20 ML Injectable Solution [SY]422These highlights do not include all the information needed to use KANJINTI safely and effectively. See full prescribing information for KANJINTI. KANJINTI ® (trastuzumab-anns) for injection, for intravenous use Initial U.S. Approval: 2019 KANJINTI (trastuzumab-anns) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differe20260310